The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

Participants Ten patients with HNF1A-diabetes and ten matched healthy controls will be recruited. Different inclusion and exclusion criteria applies for the two groups: Inclusion criteria for HNF1A-patients * Patients with HNF1A-diabetes verified by genetic testing * Patients treated with diet or sulphonylurea monotherapy * Normal haemoglobin (males 8.3-10.5 mmol/l, females 7.3-9.5 mmol/l) * Informed consent Exclusion criteria for HNF1A-patients * Nephropathy (estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73m2 and/or albuminuria) * Liver disease (serum alanine aminotransferase (ALT) and/or serum aspartate aminotransferase (AST) above 2 × normal values) * Pregnancy or breastfeeding Inclusion criteria for healthy controls * FPG ≤6 mmol/l and glycated haemoglobin (HbA1c) ≤43 mmol/mol * Normal haemoglobin as defined above * Age ≥18 years * Informed consent Exclusion criteria for healthy controls * No family history of type 1 or type 2 diabetes * Nephropathy (defined above) * Liver disease (defined above) * Pregnancy or breastfeeding